Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganagliflozin in type 2 diabetes with chronic kidney disease
NCT07116928Phase 4Not yet recruiting
- Sponsor
- Huadong Medicine
- Start
- Nov 2025
- Primary completion
- Oct 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic kidney disease (CKD) comparing Ganagliflozin with Placebo (2 arms). Primary endpoint: Average change in estimated glomerular filtration rate as measured by total slope from baseline to week 120. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
ganagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07116928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07116928.